Research Article
Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
Table 1
Background of patients who underwent oxaliplatin- or irinotecan-based therapy (n = 220).
| | Group | Oxaliplatin | | Irinotecan | | | Antibiotic-treated (n = 67) | Antibiotic-untreated (n = 53) | Antibiotic-untreated (n = 53) | Antibiotic-untreated (n = 47) |
| | Number | 67 | 53 | | 53 | 47 | | | Sex | | Male | 38 (56.7) | 29 (54.7) | 0.9901 | 33 (62.2) | 26 (55.3) | 0.481 | | Female | 29 (43.3) | 24 (45.3) | | 20 (37.8) | 21 (44.7) | | | Age (mean) | 68 (27–86) | 66 (24–83) | | 70 (32–80) | 66 (38–83) | | | Kras status | | Wild type | 35 (52.2) | 28 (52.8) | 0.6653 | 22 (41.5) | 26 (55.3) | 0.1677 | | Mutant type | 32 (48.8) | 25 (47.2) | | 31 (58.5) | 21 (44.7) | | | Line of oxaliplatin-based or irinotecan-based chemotherapy | | First line | 45 (67.1) | 36 (67.9) | 0.7569 | 21 (39.6) | 15 (31.9) | 0.4229 | | Second-line | 22 (32.8) | 17 (32.1) | | 32 (60.4) | 32 (68.1) | | | Primary site | | Left side colon | 48 (71.6) | 30 (56.6) | 0.1314 | 31 (58.5) | 33 (70.2) | 0.2229 | | Right side colon | 19 (28.4) | 23 (43.4) | | 22 (41.5) | 14 (29.8) | | | Relative dose intensity of oxaliplatin (%) | 72.1 | 71.3 | | 69.4 | 65.8 | | | Resection of primary site | | (+) | 39 (58.2) | 47 (88.7) | 0.002 | 37 (69.8) | 36 (76.6) | 0.4456 | | (−) | 28 (41.8) | 6 (11.3) | | 16 (30.2) | 11 (23.4) | | | Regimen of first-line chemotherapy (%) | | FOLFOX (plus bmab or cmab or pmab) | 53 (79.1) | 33 (62.3) | 0.0521 | | | | | SOX (plus bmab) | 9 (13.4) | 12 (22.6) | 0.1874 | | | | | CapeOX (plus bmab) | 5 (7.5) | 8 (16.9) | 0.1816 | | | | | FOLFORI (plus bmab or rmab or AFL or cmab or pmab) | | | | 38 (71.7) | 32 (68.1) | 0.6939 | | S-1 plus irinotecan | | | | 13 (24.5) | 13 (27.7) | 0.7216 | | CPT11 | | | | 2 (3.8) | 2 (4.3) | 0.9023 | | Average number of treatment (range) | | FOLFOX (plus bmab or cmab or pmab) | 17.1 (4–28) | 18.9 (6–29) | | | | | | SOX (plus bmab) | 10.5 (4–14) | 11.2 (5–13) | | | | | | CapeOX (plus bmab) | 9.5 (3–12) | 10.1 (4–13) | | | | | | FOLFORI (plus bmab or rmab or AFL or cmab or pmab) | | | | 16.9 (5–22) | 15.8 (4–23) | | | S-1 plus irinotecan | | | | 10.5 (4–16) | 11.8 (5–15) | | | CPT11 | | | | 16.2 (5–18) | 15.8 (4–21) | | | Postchemotherapy | | Irinotecan-based chemotherapy | 35 (52.2) | 27 (50.9) | 0.8879 | 0 (0) | 0 (0) | 1 | | Oxaliplatin-based chemotherapy | 0 (0) | 0 (0) | 1 | 21 (39.6) | 15 (31.9) | 0.4229 | | Cmab or pmab plus irinotecan | 7 (10.4) | 5 (9.4) | 0.9011 | 5 (9.4) | 4 (8.5) | 0.8854 | | Trifluridine, tipiracil | 19 (28.4) | 15 (28.3) | 0.9946 | 21 (39.6) | 14 (29.8) | 0.3034 | | Regorafenib | 12 (17.9) | 11 (20.8) | 0.6943 | 12 (22.6) | 13 (27.7) | 0.563 | | Trastuzumab | 1 (1.5) | 0 (0.0) | 0.3718 | 1 (1.9) | 0 (0.0) | 0.3439 | | Pembrolizumab | 1 (1.5) | 0 (0.0) | 0.3718 | 1 (1.9) | 0 (0.0) | 0.3439 |
|
|
FOLFOX: fluorouracil (5-FU) plus oxaliplatin combination therapy; SOX: S-1 plus oxaliplatin combination therapy; CapeOX: capecitabine plus oxaliplatin combination therapy; Bmab: bevacizumab. was calculated using Pearson’s chi-square test. |
